Dequan Pharmaceutical

Dequan Pharmaceutical (Dequan (Suzhou) Pharmaceutical Technology) is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. Founded in 2016 by Dr. Dequan Zou, a veteran of the global pharmaceutical industry, the company leverages its proprietary drug discovery platform to target key signaling pathways such as JAK/STAT. Its lead candidate, DQ-001, is a highly selective JAK1 inhibitor currently in Phase 2 clinical trials for indications including rheumatoid arthritis and atopic dermatitis. The company's pipeline also includes DQ-002, a selective TYK2 inhibitor, and several other programs in preclinical development. Dequan Pharmaceutical has secured significant venture capital funding from prominent investors like Oriza Holdings and Northern Light Venture Capital to advance its portfolio of targeted therapies. The company aims to provide high-quality, affordable innovative medicines to patients worldwide.